|
|
Blood, 1 January 2005, Vol. 105, No. 1, pp. 67-73.
Prepublished online as a Blood First Edition Paper on August 26, 2004; DOI 10.1182/blood-2004-04-1652.
 Previous Article | Table of Contents | Next Article 
CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS
Risk of head and neck squamous cell cancer and death in patients with Fanconi anemia who did and did not receive transplants
Philip S. Rosenberg,
Gerard Socié,
Blanche P. Alter, and
Eliane Gluckman
From the Biostatistics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services; and the Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Rockville MD; and the Service d'Hématologie/Greffe de Moelle, Hôpital Saint Louis, Paris, France.
Hematopoietic stem cell transplant (SCT) is currently the only therapy that can restore normal hematopoiesis in patients with Fanconi anemia (FA). Patients with FA have a high baseline risk of squamous cell cancers (SCCs) of the head, neck, and esophagus, and SCT conditioning may increase SCC incidence. We evaluated the risks of SCC and death in 145 patients with FA in the North American Survey (NAS) cohort who did not receive transplants, and 117 patients with FA in the Hôpital Saint Louis (SLH) cohort who did receive transplants. The age-specific hazard of SCC was 4.4-fold higher in patients who received transplants than in those who did not (P = .003), and SCCs occurred at significantly younger ages in the former (respective medians, 18 and 33 years, P = .004). Survival after SCC was similarly poor in both cohorts (P = .135, median, 13 months). The hazard of SCC increased at a greater than linear rate, to 4.4% per year by age 40 in NAS and 4.7% per year by 10 years after transplant in SLH. In SLH, the hazard of non-SCC death was biphasic, declining significantly (P = .004) from 7.1% per month during the first 6 months after transplant to 0.13% per month (1.6% per year) after the first year. Acute and chronic graft-versus-host diseases were significant SCC risk factors. Adverse event rates in these cohorts provide historical control rates to assess emerging therapies for FA.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
B. P. Alter, N. Giri, S. A. Savage, and P. S. Rosenberg
Cancer in dyskeratosis congenita
Blood,
June 25, 2009;
113(26):
6549 - 6557.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. O. Pinto, T. Leblanc, D. Chamousset, G. Le Roux, B. Brethon, B. Cassinat, J. Larghero, J.-P. de Villartay, D. Stoppa-Lyonnet, A. Baruchel, et al.
Diagnosis of Fanconi anemia in patients with bone marrow failure
Haematologica,
April 1, 2009;
94(4):
487 - 495.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Janin, H. Murata, C. Leboeuf, J.-M. Cayuela, E. Gluckman, L. Legres, A. Desveaux, M. Varna, P. Ratajczak, J. Soulier, et al.
Donor-derived oral squamous cell carcinoma after allogeneic bone marrow transplantation
Blood,
February 19, 2009;
113(8):
1834 - 1840.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Si, A. C. Pulliam, Y. Linka, S. Ciccone, C. Leurs, J. Yuan, O. Eckermann, S. Fruehauf, S. Mooney, H. Hanenberg, et al.
Overnight transduction with foamyviral vectors restores the long-term repopulating activity of Fancc-/- stem cells
Blood,
December 1, 2008;
112(12):
4458 - 4465.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. J. T. van Zeeburg, P. J. F. Snijders, T. Wu, E. Gluckman, J. Soulier, J. Surralles, M. Castella, J. E. van der Wal, J. Wennerberg, J. Califano, et al.
Clinical and Molecular Characteristics of Squamous Cell Carcinomas From Fanconi Anemia Patients
J Natl Cancer Inst,
November 19, 2008;
100(22):
1649 - 1653.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. S. Rosenberg, B. P. Alter, and W. Ebell
Cancer risks in Fanconi anemia: findings from the German Fanconi Anemia Registry
Haematologica,
April 1, 2008;
93(4):
511 - 517.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Locatelli, M. Zecca, A. Pession, G. Morreale, D. Longoni, P. Di Bartolomeo, F. Porta, F. Fagioli, B. Nobili, M. E. Bernardo, et al.
The outcome of children with Fanconi anemia given hematopoietic stem cell transplantation and the influence of fludarabine in the conditioning regimen: a report from the Italian pediatric group
Haematologica,
October 1, 2007;
92(10):
1381 - 1388.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B Perez-Ordonez, M Beauchemin, and R C K Jordan
Molecular biology of squamous cell carcinoma of the head and neck.
J. Clin. Pathol.,
May 1, 2006;
59(5):
445 - 453.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C G Steward and A Jarisch
Haemopoietic stem cell transplantation for genetic disorders
Arch. Dis. Child.,
December 1, 2005;
90(12):
1259 - 1263.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Van Waes
Head and Neck Squamous Cell Carcinoma in Patients With Fanconi Anemia
Arch Otolaryngol Head Neck Surg,
July 1, 2005;
131(7):
640 - 641.
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. P. Alter
Bone Marrow Failure: A Child Is Not Just a Small Adult (But an Adult Can Have a Childhood Disease)
Hematology,
January 1, 2005;
2005(1):
96 - 103.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. C. Guinan
Aplastic Anemia: Management of Pediatric Patients
Hematology,
January 1, 2005;
2005(1):
104 - 109.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
